ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Classificação em ações
#19245
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Preço da ação
$0.3799409
Valor de mercado
$159.21M
Variação (1 dia)
-0.34%
Variação (1 ano)
-71.81%
País
CN
Negociar ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Categoria
Healthcare
EPS de ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da ImmuneOnco Biopharmaceuticals (Shanghai) Inc., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da ImmuneOnco Biopharmaceuticals (Shanghai) Inc. de 2026 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
